Investigation on bribery in pharmaceutical industry in China

Guide: Reuters reported on Thursday that Chinese authorities have visited the offices of Belgian pharmaceutical maker UCB, marking the expansion of investigations into bribery in the pharmaceutical industry by Chinese authorities after GlaxoSmithKline Beijing time, July 19, early morning news, Reuters reported on Thursday that Chinese authorities had visited the offices of Belgian pharmaceutical maker UCB, marking the expansion of the investigation into bribery in the pharmaceutical industry by Chinese authorities after GlaxoSmithKline Chinese police have previously accused GlaxoSmithKline of offering bribes to Chinese officials and doctors to boost sales, as well as raising the price of drugs, showing a strong stance against the improper conduct of multinational companies operating in China "The Chinese Administration for Industry and Commerce has visited us," said a spokesman for Belgium's yoshibi As part of their investigation into several pharmaceutical companies in China, including Chinese companies and foreign companies like us, our Shanghai office has been visited by the Administration for Industry and Commerce in the past 48 hours " The spokesman added that the purpose of the SAIC's visit to the company's Shanghai office was to seek relevant compliance information China's State Administration for Industry and commerce is one of the three antitrust regulators in charge of market supervision The agency's investigation activities often overlap those of the national development and Reform Commission, the top regulator, which recently launched a price manipulation investigation of domestic and international pharmaceutical giants, including GlaxoSmithKline, Merck and anstelai.